Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 15/20 | 0.37 |
| ▸ | CCND1 | P24385 | 15/20 | 0.37 |
| ▸ | PARP1 | P09874 | 3/20 | 0.36 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.34 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.34 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TYMS | P04818 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14336773 | 0.84 | TYMS (0.35) | TYMS | |
| SCHEMBL14336578 | 0.74 | HPGD (0.39) | CDK4CCND1PARP1CCNE2CCNE1 | |
| SCHEMBL27407446 | 0.73 | SRC (0.32) | — | |
| SCHEMBL29308982 | 0.69 | PARP1 (0.45) | CDK4CCND1PARP1CCNE2CCNE1 | |
| SCHEMBL12149780 | 0.69 | PARP1 (0.44) | CDK4CCND1PARP1TYMS | |
| SCHEMBL12702573 | 0.69 | PI4KA (0.41) | PARP1 | |
| SCHEMBL27407758 | 0.68 | — | — | |
| SCHEMBL14725446 | 0.68 | PDE2A (0.41) | PARP1TYMS | |
| SCHEMBL22873334 | 0.68 | TNKS (0.33) | — | |
| SCHEMBL23366309 | 0.67 | TYMS (0.38) | TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209439-A1 | NUCLEOTIDE ANALOGUE FOR SEQUENCING | BGI SHENZHEN (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240067673-A1 | MODIFIED NUCLEOSIDE OR NUCLEOTIDE | BGI SHENZHEN (CN) | 2024-02-29 | — | — | US | disclosed |
| US-11814450-B2 | Polymeric solid support for oligonucleotide synthesis | HONGENE BIOTECH CORPORATION (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814450-B2 | Polymeric solid support for oligonucleotide synthesis | HONGENE BIOTECH CORPORATION (US) | 2023-11-14 | — | — | US | disclosed |
| US-11649260-B2 | Functionalized N-acetylgalactosamine nucleosides | HONGENE BIOTECH CORPORATION (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649260-B2 | Functionalized N-acetylgalactosamine nucleosides | HONGENE BIOTECH CORPORATION (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230130509-A1 | POLYMERIC SOLID SUPPORT FOR OLIGONUCLEOTIDE SYNTHESIS | HONGENE BIOTECH CORPORATION | 2023-04-27 | — | — | US | disclosed |
| US-20230130509-A1 | POLYMERIC SOLID SUPPORT FOR OLIGONUCLEOTIDE SYNTHESIS | HONGENE BIOTECH CORPORATION | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209439-A1 | NUCLEOTIDE ANALOGUE FOR SEQUENCING | NT5C3B, NT5E, NUDT1 | CDK4 1451/4885CCND1 3637/4885PARP1 49/4885 |
| US-11649260-B2 | Functionalized N-acetylgalactosamine nucleosides | FUT6, B3GNT2, GALNT6 | CDK4 4336/4885CCND1 4414/4885PARP1 534/4885 |
| US-20240067673-A1 | MODIFIED NUCLEOSIDE OR NUCLEOTIDE | NT5C3B, NT5E, NT5C2 | CDK4 604/4885CCND1 2354/4885PARP1 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.